ABSTRACT
Context: COVID-19 is linked to substantial increases in morbidity and mortality around the globe. Cardiovascular disease (CVD), diabetes, hypertension, and obesity are all risk factors for a more severe case of COVID-19 and an increased risk of death. The purpose of this research was to demonstrate a link with covid19 and the development of cardiovascular disease in previously healthy covid patients. From June 2021 to June 2022, a cross-sectional observational research was carried out at the National Heart Institute in Egypt. Patients with covid-19 linked to cardiovascular disorders made about 20% of the sample, which comprised 200 hospital inpatients. The outcomes were as follows: 79 patients (39.5% of the total) experienced bleeding, 65 patients (32.5% of the total) experienced HF, 21 patients (10.5% of the total) experienced stroke, 10 patients (5%) experienced TIA, 21 patients (10.5% of the total) experienced tachycardia, 14 patients (7% of the total) experienced VA, 12 patients (6% of the total) experienced bradycardia, 11 patients (5.5%) experienced AF, 25 patients (12.5% of Of the 121 patients diagnosed with MI, 121 (or 60.5%) died before receiving PCI. Our research shows that Covid-19 is linked to preexisting cardiovascular illness. Among COVID-19 patients with cardiovascular problems, age, smoking, high blood pressure, diabetes, chronic obstructive pulmonary disease, and chronic kidney disease are all strong independent predictors of death. Patients with covid -19 who develop MACE or HF have an increased risk of dying. [ FROM AUTHOR] Copyright of Journal of Cardiovascular Disease Research (Journal of Cardiovascular Disease Research) is the property of Journal of Cardiovascular Disease Research and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)
ABSTRACT
BackgroundWhile the second wave of COVID-19 pandemic almost reached its climax, unfortunately, new viral strains are rapidly spreading, and numbers of infected young adults are rising. Consequently, chest high-resolution computed tomography (HRCT) demands are increasing, regarding patients' screening, initial evaluation and follow up. This study aims to evaluate the detection accuracy of ultra-low-dose chest CT in comparison with the routine low-dose chest CT to reduce the irradiation exposure hazards.ResultsThis study was prospectively conducted on 250 patients during the period from 15th December 2020 to 10th February 2021. All of the included patients were clinically suspected of COVID-19 infection. All patients were subjected to routine low-dose (45 mAs) and ultra-low-dose (22 mAs) chest CT examinations. Finally, all patients had confirmatory PCR swab tests and other dedicated laboratory tests. They included 149 males and 101 females (59.6%:40.4%). Their age ranged from 16 to 84 years (mean age 50 ± 34 SD). Patients were divided according to body weight;104 patients were less than 80 kg, and 146 patients were more than 80 kg. HRCT findings were examined by two expert consultant radiologists independently, and data analysis was performed by other two expert specialist and consultant radiologists. The inter-observer agreement (IOA) was excellent (96–100%). The ultra-low-dose chest CT reached 93.53–96.84% sensitivity and 90.38–93.84% accuracy. The signal-to-noise ratio (SNR) is 12.8:16.1;CTDIvol (mGy) = 1.1 ± 0.3, DLP (mGy cm) = 42.2 ± 7.9, mean effective dose (mSv/mGy cm) = 0.59 and absolute cancer risk = 0.02 × 10-4.ConclusionUltra-low-dose HRCT can be reliably used during the second wave of COVID-19 pandemic to reduce the irradiation exposure hazards.
ABSTRACT
OBJECTIVE: To assess the influence of the COVID-19 pandemic on the medication adherence and follow-up of glaucoma patients in the Nile Delta region. SETTING: A tertiary care center in the Nile Delta region, Egypt. STUDY DESIGN: An observational, cross-sectional study. PARTICIPANTS: Patients' records (2019-2020; group A) and (2020-2021; group B) were assessed for missed follow-up visits, medication adherence, number of trabeculectomies performed, and uncontrolled patients. In addition, a telephone-based questionnaire involving randomly chosen 200 patients from B.G.U. was carried out to clarify the potential causes of poor patients' compliance. RESULTS: There was a marked decline in the number of newly diagnosed patients and patients on regular follow-up with incidence rates 0.208 and 0.088 in group (A) and group (B), respectively (P-value < 0.0001). The number of compliant patients in group B decreased with an incidence rate difference of 0.312. The number of trabeculectomies declined in group (B) with an incidence rate in group (A) 0.131 compared to 0.081 in group (B). On the other hand, the number of uncontrolled glaucoma patients increased in group B with an incidence rate difference -0.231 between the two groups. 21.5% of patients who participated in the questionnaire identified financial issues as the leading cause of non-compliance. Comorbidities (19.5%), lockdown and transportation difficulties were also highlighted. CONCLUSION: COVID-19 had greatly hampered glaucoma care in the Nile Delta region. As a result, we need to implement new technologies like telemedicine and improve patients' awareness of glaucoma care. Training orthoptists and using mobile glaucoma care services would also be helpful ways of managing glaucoma during that pandemic.